These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 841320)

  • 1. Conditioned narcotic withdrawal in humans.
    O'Brien CP; Testa T; O'Brien TJ; Brady JP; Wells B
    Science; 1977 Mar; 195(4282):1000-2. PubMed ID: 841320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditioning of narcotic abstinence symptoms in human subjects.
    O'Brien CP; O'Brien TJ; Mintz J; Brady JP
    Drug Alcohol Depend; 1975 Dec; 1(2):115-23. PubMed ID: 1235105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditioning in human opiate addicts.
    O'Brien CP; Testa T; O'Brien TJ; Greenstein R
    Pavlov J Biol Sci; 1976; 11(4):195-202. PubMed ID: 995439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular absorption of naloxone in narcotic addicts.
    Duncalf D; Jeyaram C; Tarter R; Foldes FF
    Int J Addict; 1975; 10(1):23-7. PubMed ID: 1126766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects.
    Kanof PD; Handelsman L; Aronson MJ; Ness R; Cochrane KJ; Rubinstein KJ
    J Pharmacol Exp Ther; 1992 Jan; 260(1):355-63. PubMed ID: 1731046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental analysis of conditioning factors in human narcotic addiction.
    O'Brien CP
    Pharmacol Rev; 1975 Dec; 27(4):533-43. PubMed ID: 1223916
    [No Abstract]   [Full Text] [Related]  

  • 8. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal.
    Li Y; Wang H; Qi K; Chen X; Li S; Sui N; Kirouac GJ
    Physiol Behav; 2011 Jan; 102(1):42-50. PubMed ID: 20951152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circling behavior after narcotic drugs and during naloxone-precipitated abstinence in rats with unilateral nigral lesions.
    Iwamoto ET; Loh HH; Way EL
    J Pharmacol Exp Ther; 1976 Jun; 197(3):503-16. PubMed ID: 945346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The discriminative stimulus properties of naloxone during dissociative learning in a Y maze in morphine-dependent rats].
    Bespalov AIu; Medvedev IO; Dravolina OA; Zvartau EE
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1999; 49(1):96-105. PubMed ID: 10330710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditioned opioid withdrawal decreases nociceptin/orphanin FQ levels in the frontal cortex and olfactory tubercle.
    Walker JR; Terenius L; Koob GF
    Neuropsychopharmacology; 2002 Aug; 27(2):203-11. PubMed ID: 12093594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing endocannabinoid metabolism with the fatty acid amide hydrolase inhibitor, URB597, fails to modify reinstatement of morphine-induced conditioned floor preference and naloxone-precipitated morphine withdrawal-induced conditioned floor avoidance.
    McCallum AL; Limebeer CL; Parker LA
    Pharmacol Biochem Behav; 2010 Oct; 96(4):496-500. PubMed ID: 20643159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: Treatment of accidental naltrexone-induced withdrawal.
    Volavka J; Resnick RB
    Am J Psychiatry; 1976 Feb; 133(2):233. PubMed ID: 56139
    [No Abstract]   [Full Text] [Related]  

  • 18. [Drug therapy in overdose and withdrawal syndrome in heroin addicts].
    Arrizabalaga Cuesta C; Zulaica D
    Rev Enferm; 1985 Feb; 8(78):23-5. PubMed ID: 3845677
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical assessment of physical dependence potential of dihydroetorphine hydrochloride (DHE)].
    Ge Y; Li M; Sun WL; Cai ZJ
    Yao Xue Xue Bao; 1994; 29(4):256-60. PubMed ID: 7976340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug therapy of opioid withdrawal].
    Cortese S; Risso M
    Vertex; 2008; 19(77):522-6. PubMed ID: 18443666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.